Revium Rx. 8-K

What Happened
Revium Rx (RVRC) filed a Form 8‑K reporting management and board changes: the Board appointed Amir Avraham as the company’s permanent Chief Executive Officer, effective February 1, 2026 (he had been interim CEO since May 22, 2025). On April 14, 2026 the Board also appointed Shlomi Schwartzblat as a director and Chairman of the Board, with his term expiring at the 2026 annual meeting.

Key Details

• Amir Avraham’s employment agreement: monthly salary of NIS 55,000, eligibility for an annual discretionary cash bonus, and a one‑time $50,000 bonus if at least $5.0 million in new equity investments (excluding existing shareholders) are completed within 18 months from Feb 1, 2026 (i.e., by Aug 1, 2027), subject to continued employment and Board approval.
• Equity awards: initial grant of options to purchase 1,300,000 shares (vesting to commence Feb 1, 2026); up to 600,000 additional options contingent on (a) $3.0M in investments (300,000 options) and (b) a successful M&A transaction (300,000 options). Total potential options = 1,900,000, subject to the Company’s Global Share Incentive Plan and required pool increase.
• Other terms: customary benefits, expense reimbursement, indemnification, D&O insurance, and 12‑month confidentiality, non‑competition and non‑solicitation covenants.
• Shlomi Schwartzblat’s background: founder/CEO of Gavriel Ventures (since 2015); prior roles in venture/early‑stage investing; holds an MBA and B.Sc. No related‑party transactions or arrangements requiring disclosure were reported.

Why It Matters
These appointments provide leadership continuity (interim CEO made permanent) and a new Board chair, which can influence strategy execution and investor confidence. The CEO’s compensation ties significant upside to new equity investments and M&A activity, signaling management incentives to pursue capital raises and strategic transactions. Investors should note potential share dilution from up to 1,900,000 options and monitor any announced capital raises or M&A activity referenced by the company going forward.